Solana (HSDT) & The Competition Critical Survey

Solana (NASDAQ:HSDT) is one of 342 publicly-traded companies in the “Financial Services” industry, but how does it contrast to its peers? We will compare Solana to related companies based on the strength of its valuation, dividends, analyst recommendations, risk, earnings, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Solana and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	2	0	2.25
Solana Competitors	1970	6870	11619	443	2.50

Solana presently has a consensus price target of $4.00, indicating a potential upside of 91.39%. As a group, “Financial Services” companies have a potential downside of 1.58%. Given Solana’s higher probable upside, research analysts clearly believe Solana is more favorable than its peers.

Volatility and Risk

Solana has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Solana’s peers have a beta of 2.49, meaning that their average stock price is 149% more volatile than the S&P 500.

Insider & Institutional Ownership

18.6% of Solana shares are held by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are held by institutional investors. 14.4% of Solana shares are held by company insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Solana and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,302.78%	-41.86%	-18.53%
Solana Competitors	-409.62%	-15.98%	-6.09%

Earnings and Valuation

This table compares Solana and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Solana	$12.07 million	-$40.89 million	-0.07
Solana Competitors	$24.41 billion	$1.07 billion	8.38

Solana’s peers have higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Solana peers beat Solana on 12 of the 13 factors compared.

Solana Company Profile

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.